Association of serum zinc, selenium, nickel, cobalt and prostate-specific antigen levels with prostate cancer: a case-control study
DOI:
https://doi.org/10.18203/2349-2902.isj20260837Keywords:
Biomarkers, Cobalt, Nickel, Nigeria, PSA, Prostate cancer, Selenium, ZincAbstract
Background: Prostate cancer (PCa) is a leading cause of cancer morbidity and mortality in men, with growing incidence in Nigeria. While prostate-specific antigen (PSA) remains the primary screening tool, its limited specificity necessitates exploration. Zinc (Zn), selenium (Se), nickel (Ni) and cobalt (Co) have been implicated in carcinogenesis, but their roles in PCa among Nigerian men remain under researched. To evaluate the association between serum Zn, Se, Ni, Co and prostate-specific antigen (PSA) levels in histologically confirmed PCa.
Methods: This was a prospective case-control study conducted among 81 men presenting with bladder outlet obstruction in two Nigerian hospitals. Forty-one patients with histologically confirmed PCa and 40 with benign prostatic disease (controls). Serum Zn, Se, Ni and Co levels were measured using atomic absorption spectrophotometry and PSA was determined via standard immunoassay. Demographic and biochemical data were analyzed.
Results: PSA was significantly elevated in PCa patients (18±5 ng/ml) versus controls (2±1 ng/ml, p<0.001). PCa patients had lower Zn (0.34±0.66 vs. 0.79±0.42 µg/ml, p<0.001) and Co (0.015±0.010 vs. 0.20±0.36 µg/ml, p<0.001), while Ni was higher (0.52±0.42 vs. 0.30±0.08 µg/ml) but not statistically significant (p=0.600). Se levels were slightly lower in PCa (0.14±0.07 µg/ml) compared to controls (0.17±0.07 µg/ml), without statistical significance (p=0.073).
Conclusions: PCa in Nigerian men is associated with PSA elevation, reduced serum Zn and Co and a trend toward higher Ni and lower Se. Zn depletion aligns with established literature, whereas reduced Co represents a novel observation warranting further study. Trace element profiling, alongside PSA, may enhance detection of PCa.
Metrics
References
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. European Urol Oncol. 2021;1;4(6):877-92. DOI: https://doi.org/10.1016/j.euo.2021.09.006
Igbokwe MC, Badmus TA, Salako AA, Obiajunwa EI, Olasehinde O, Igbokwe CA, et al. Profile of tissue selenium concentration in a cohort of nigerian men with prostate cancer. J Cancer Sci Clin Therap. 2021;5:576-86.
Aligbe JU, Forae GD. Prostatic tumours among Nigerian males: A private practice experience in Benin-City, South-South, Nigeria. Nigerian Postgraduate Med J. 2013;1;20(3):193-6. DOI: https://doi.org/10.4103/1117-1936.164709
Akinremi TO, Ogo CN, Olutunde AO. Review of prostate cancer research in Nigeria. Inf Agents Cancer. 2011;1;6(2):8. DOI: https://doi.org/10.1186/1750-9378-6-S2-S8
Emiogun EF, Williams O, Obafunwa JO. Epidemiology of prostate cancer in Nigeria: Observations at Lagos state university teaching hospital. Cancer Heal Disparities. 2020;4:1-9.
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;20;10(2):63. DOI: https://doi.org/10.14740/wjon1191
Dunn MW, Kazer MW. Prostate cancer overview. Sem Oncol Nurs. 2011;27(4):241–50. DOI: https://doi.org/10.1016/j.soncn.2011.07.002
Raphael JE, Danagogo O. Pilot study on the locoregional demographics of prostate cancer in River State, Nigeria. Nigerian Medical Journal: J Nigeria Med Association. 2022;62(6):340.
Jaiteh L. Cancer scenario in the Gambia-Africa. Ann Oncol Res Therapy. 2024;1;4(2):53-4. DOI: https://doi.org/10.4103/aort.aort_24_24
Babb C, Urban M, Kielkowski D, Kellett P. Prostate cancer in South Africa: pathology based national cancer registry data (1986–2006) and mortality rates (1997–2009). Prostate Cancer. 2014;2(1):419801. DOI: https://doi.org/10.1155/2014/391257
Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013;1;1(2):47-58. DOI: https://doi.org/10.12954/PI.12014
Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nature Rev Dis Prim. 2016;5;2(1):1-5. DOI: https://doi.org/10.1038/nrdp.2016.31
Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, staging and management of prostate cancer. Med Sci. 2020;8(3):28. DOI: https://doi.org/10.3390/medsci8030028
Iheanacho CO, Enechukwu OH. Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review. Cancer Cau Control. 2025;36(1):1-12. DOI: https://doi.org/10.1007/s10552-024-01917-w
Okwor CJ, Nnakenyi ID, Agbo EO, Nweke M. Sensitivity and specificity of prostate-specific antigen and its surrogates towards the detection of prostate cancer in sub-Saharan Africa: a systematic review with meta-analysis. African J Urol. 2023;5;29(1):41. DOI: https://doi.org/10.1186/s12301-023-00372-4
Chung Y, Hong SK. Evaluating prostate cancer diagnostic methods: The role and relevance of digital rectal examination in modern era. Invest Clin Urol. 2025;7;66(3):181. DOI: https://doi.org/10.4111/icu.20240456
Johnson JR, Woods-Burnham L, Hooker Jr SE, Batai K, Kittles RA. Genetic contributions to prostate cancer disparities in men of West African descent. Front Oncol. 2021;11:770500. DOI: https://doi.org/10.3389/fonc.2021.770500
Tyagi B, Chandrasekaran B, Tyagi A, Shukla V, Saran U, Tyagi N, et al. Exposure of environmental trace elements in prostate cancer patients: A multiple metal analysis. Toxicol Appl Pharmacol. 2023;479:116728. DOI: https://doi.org/10.1016/j.taap.2023.116728
Tshoni UA, Mbonane TP, Rathebe PC. The role of trace metals in the development and progression of prostate cancer. International J Mol Sci. 2024;25(19):10725. DOI: https://doi.org/10.3390/ijms251910725
Fu H, Murali A, Damodaran C. Exposure of environmental trace elements in prostate cancer patients: Risk analysis in multiple levels. InUrologic Oncology: Sem Original Invest. 2024;42:88. DOI: https://doi.org/10.1016/j.urolonc.2024.01.245
Habib A, Jaffar G, Khalid MS, Hussain Z, Zainab SW, Ashraf Z, et al. Risk factors associated with prostate cancer. J Drug Del Therap. 2021;11(2):188-93. DOI: https://doi.org/10.22270/jddt.v11i2.4758
Saleh SA, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of selenium, zinc, copper, manganese and iron in prostate cancer patients. Curr Urol. 2020;14(1):44-9. DOI: https://doi.org/10.1159/000499261
Silvera SA, Rohan TE. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control. 2007;18(1):7-27. DOI: https://doi.org/10.1007/s10552-006-0057-z
Popescu E, Stanescu AM. Trace elements and cancer. Mod. Med. 2019;26(4):169-77. DOI: https://doi.org/10.31689/rmm.2019.26.4.169
Mulware SJ. Trace elements and carcinogenicity: a subject in review. Biotech. 2013;3(2):85-96. DOI: https://doi.org/10.1007/s13205-012-0072-6
Tan HW, Mo HY, Lau AT, Xu YM. Selenium species: current status and potentials in cancer prevention and therapy. Int J Mol Sci. 2018;25;20(1):75. DOI: https://doi.org/10.3390/ijms20010075
Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52(11):1261-72. DOI: https://doi.org/10.1002/mnfr.200800103
Chakravarty PK. Evaluation of serum zinc level under malignant condition and its possible implication on improving cell-mediated immunity during cancer progression. World J Oncol. 2011;2(1):16–23. DOI: https://doi.org/10.4021/wjon256e
Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto K, Hasegawa H, et al. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma. PLoS One. 2020;28;15(8):237370. DOI: https://doi.org/10.1371/journal.pone.0237370
Devi V, Chaudhary V, Sharma M, Kumari S, Murti K, Meenakshi S, et al. Serum levels of heavy metals in patients with prostate cancer: A systematic review and meta-analysis. Biol Trace Elem Res. 2025;8:1-10.
Zhao L, Islam R, Wang Y, Zhang X, Liu LZ. Epigenetic regulation in chromium-, nickel-and cadmium-induced carcinogenesis. Cancers. 2022;23;14(23):5768. DOI: https://doi.org/10.3390/cancers14235768
Genchi G, Carocci A, Lauria G, Sinicropi MS, Catalano A. Nickel: Human health and environmental toxicology. Int J Envir Res Publ Heal. 2020;17(3):679. DOI: https://doi.org/10.3390/ijerph17030679
Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M. BMI trajectories and risk of overall and grade‐specific prostate cancer: an observational cohort study among men seen for prostatic conditions. Cancer Med. 2018;7(10):5272-80. DOI: https://doi.org/10.1002/cam4.1747
Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Canc. 2015;136(8):1940-7. DOI: https://doi.org/10.1002/ijc.29238
Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27(15):2450-6. DOI: https://doi.org/10.1200/JCO.2008.19.9810
Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50. Cancer. 2011;117(6):1210-9. DOI: https://doi.org/10.1002/cncr.25568
Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer?. European J Cancer. 2006;42(15):2463-71. DOI: https://doi.org/10.1016/j.ejca.2006.02.027
Yildiz A, Kaya Y, Tanriverdi O. Effect of the interaction between selenium and zinc on DNA repair in association with cancer prevention. Journal of Cancer Prevention. 2019;30;24(3):146. DOI: https://doi.org/10.15430/JCP.2019.24.3.146
Devi V, Chaudhary V, Sharma M, Kumari S, Murti K, Meenakshi S, et al. Serum levels of heavy metals in patients with prostate cancer: A systematic review and meta-analysis. Biol Trace Element Res. 2025;8:1-10. DOI: https://doi.org/10.1007/s12011-024-04510-z
Pietrzak S, Marciniak W, Derkacz R, Matuszczak M, Kiljańczyk A, Baszuk P, et al. Cobalt serum level as a biomarker of cause-specific survival among prostate cancer patients. Cancers. 2024;16(15):2618. DOI: https://doi.org/10.3390/cancers16152618
Downloads
Published
How to Cite
Issue
Section
